Evidence map›Paper›PMID 41618691›Full record

ArticleBrain pathology (Zurich, Switzerland)2026

Rapid generation of prion disease models using AAV-delivered PrP variants in knockout mice.

Maitena San-Juan-Ansoleaga, Eva Fernández-Muñoz, Jorge M Charco, Enric Vidal, Diego Herrero-Martínez, Josu Galarza-Ahumada, Cristina Sampedro-Torres-Quevedo, Samanta Giler, Mariví Geijo, Gloria González-Aseguinolaza and 2 more

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maitena San-Juan-AnsoleagaCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID https://orcid.org/0000-0001-7968-510X
Eva Fernández-MuñozCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Jorge M CharcoCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID https://orcid.org/0000-0003-3476-1855
Enric VidalIRTA, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Diego Herrero-MartínezDNA & RNA Medicine Division, Gene Therapy for Rare Diseases Department, Center for Applied Medical Research (CIMA), University of Navarra, IdisNA, Pamplona, Spain.
Josu Galarza-AhumadaCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Cristina Sampedro-Torres-QuevedoCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Samanta GilerIRTA, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Mariví GeijoAnimal Health Department, NEIKER-Basque Institute for Agricultural Research and Development, Basque Research and Technology Alliance (BRTA), Derio, Spain.
Gloria González-AseguinolazaDNA & RNA Medicine Division, Gene Therapy for Rare Diseases Department, Center for Applied Medical Research (CIMA), University of Navarra, IdisNA, Pamplona, Spain.
Hasier ErañaCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Joaquín CastillaCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID https://orcid.org/0000-0002-2216-1361

Funding

Creutzfeldt-Jakob Disease Foundation 2024 grantEuropean Regional Development Fund EFA031/01 NEURO-COOPMinisterio de Ciencia e Innovación CEX2021-001136-SMinisterio de Ciencia e Innovación PID2021-122201OB-C21Ministerio de Ciencia e Innovación PID2021-122201OB-C22Ministerio de Ciencia e Innovación PID2024-160022OB-I00
6 · The paper itself

Abstract

The study of prion biology has traditionally relied on transgenic mouse models, which, while valuable, require significant time and resources to develop. Here, we present a rapid and flexible alternative using adeno-associated virus (AAV) vectors to express modified prion proteins in PrP-knockout (PrP-KO) mice. Through systematic evaluation of multiple AAV constructs, we optimized vector design by comparing different CNS-specific promoters and regulatory elements to generate prion disease models capable of faithfully propagating the inoculated prion strain. We identified an optimized AAV construct incorporating the human synapsin promoter, MVM enhancer, and WPRE posttranscriptional regulatory element encapsidated in the AAV9P31 serotype to drive neuron-specific expression of modified mouse PrP (W144Y epitope) and bank vole I109 PrP (W145Y epitope). Following intravenous administration, we achieved brain-wide expression at levels comparable to or even exceeding endogenous PrP in some regions. When challenged with mouse-adapted RML prions or human Gerstmann-Sträussler-Scheinker (GSS-A117V) disease-causing prions, AAV-PrP mice developed characteristic signs of prion disease with accelerated kinetics (58-106 days post-inoculation for RML; 105-112 dpi for GSS-A117V), displaying features typical of each strain. Serial transmission of AAV-generated RML prions to wild-type mice confirmed preservation of strain-specific properties (165 ± 4 dpi), validating the authenticity of prion propagation in this system. This approach provides a versatile platform for rapidly generating and studying prion variants in an authentic brain environment. By reducing model generation time from months to weeks, this system enables accelerated investigation of prion structure-function relationships, strain properties, and therapeutic strategies, with potential applications extending to other protein misfolding diseases.

Indexed as

DependovirusDisease Models, AnimalPrion DiseasesPrion ProteinsPrionsAnimalsBrainGenetic VectorsHumansMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicPrion ProteinsPrionsAAVGerstmann‐Sträussler‐Scheinker (GSS)‐A117Vprionprion propagationprion strainsRMLtransgenic mice: AAV‐mediated PrP deliverytransmissible spongiform encephalopathies

Identifiers

PMID41618691
PMCPMC13239493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.